Biogen has opened Phase 3 studies of salanersen, a once-a-year SMA treatment. The first participants have been dosed in the US and Japan.
News
News
Articles, medical news, announcements about community actions and progress of the cause.
Showing 1 - 5 of 5 Posts
On September 11, 2026, the FDA approved Isembyld (apitegromab), the first SMA therapy that targets muscle directly. In the EU the application was withdrawn and will be resubmitted.